The US Supreme Court looks likely to dismiss a high-profile case challenging the US Food and Drug Administration’s relaxation of the abortion pill mifepristone’s risk evaluation and mitigation strategy (REMS) on grounds that the doctor group suing the agency lacks standing.
The move should avoid the potential seismic shift in the country’s drug regulatory regime that industry and FDA feared the...





